These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29488399)

  • 1. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System.
    Dreon DM; Hannon TM; Cross B; Carter BJ; Mercer NS; Nguyen JH; Tran A; Melendez PA; Morales N; Nelson JE; Tan MH
    J Diabetes Sci Technol; 2018 Jul; 12(4):817-827. PubMed ID: 29488399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of "Laboratory and Benchtop Performance of a Mealtime Insulin Delivery System".
    Zijlstra E
    J Diabetes Sci Technol; 2018 Jul; 12(4):828-830. PubMed ID: 29619894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of glide force characteristics between 2 prefilled insulin lispro pens.
    Rees TM; Lennartz AH; Ignaut DA
    J Diabetes Sci Technol; 2015 Mar; 9(2):316-9. PubMed ID: 25591858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection force and dose accuracy of FlexTouch for the delivery of a new basal insulin.
    Götzche D; Rasmussen BØ; Pedersen MT; Sparre T; Bucher D; Niemeyer M
    Expert Opin Drug Deliv; 2013 Dec; 10(12):1613-9. PubMed ID: 24256325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.
    Bergenstal RM; Peyrot M; Dreon DM; Aroda VR; Bailey TS; Brazg RL; Frias JP; Johnson ML; Klonoff DC; Kruger DF; Ramtoola S; Rosenstock J; Serusclat P; Weinstock RS; Naik RG; Shearer DM; Zraick V; Levy BL;
    Diabetes Technol Ther; 2019 May; 21(5):273-285. PubMed ID: 31025878
    [No Abstract]   [Full Text] [Related]  

  • 6. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic outcomes with the conversion of insulin delivery methods in hospitals.
    Kelton KA; Perk S; Loveland S; Perez-Nieves M; Fu H; Peng X
    J Med Econ; 2017 May; 20(5):533-540. PubMed ID: 28133990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
    Haahr H; Fita EG; Heise T
    Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR; Bell MA; Heyob JA; Storms SM
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Patient-Driven Approach to Manage Mealtime Insulin Titration: Tools From the AUTONOMY Study.
    Camacho A; Johnson J; Bonner JS; Glass LC
    Diabetes Educ; 2016 Jun; 42(3):271-80. PubMed ID: 27066804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump.
    Senesh G; Bushi D; Neta A; Yodfat O
    J Diabetes Sci Technol; 2010 Jan; 4(1):104-10. PubMed ID: 20167173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch.
    Peyrot M; Dreon D; Zraick V; Cross B; Tan MH
    Diabetes Ther; 2018 Feb; 9(1):297-307. PubMed ID: 29327220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
    Hövelmann U; Heise T; Nosek L; Sassenfeld B; Thomsen KMD; Haahr H
    Clin Drug Investig; 2017 May; 37(5):503-509. PubMed ID: 28185141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary detection of rapid-acting insulin analogs in healthy humans.
    Judák P; Coppieters G; Lapauw B; Van Eenoo P; Deventer K
    Drug Test Anal; 2020 Nov; 12(11-12):1629-1635. PubMed ID: 32386349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.
    Wang T; Conrad KA; van Brunt K; Rees TM
    J Diabetes Sci Technol; 2016 Jul; 10(4):923-31. PubMed ID: 26920640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
    Lindström T; Hedman CA; Arnqvist HJ
    Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.